论文部分内容阅读
目的探讨固本防哮饮防治支气管哮喘的可能作用机制。方法将70只BALB/c小鼠随机分为正常组、模型组、孟鲁司特钠组和固本防哮饮低、中、高剂量组及固本防哮饮预防组,每组10只。除正常组外,其余各组小鼠采用卵蛋白致敏和激发联合呼吸道合胞病毒感染的方法,建立支气管哮喘模型。孟鲁司特钠组给予孟鲁司特钠片1.5 mg/(kg·d),固本防哮饮低、中、高剂量组分别给予固本防哮饮13.5、27.0、54.0 g/(kg·d),以上各组均于造模第56天开始灌胃给予相应药物,每天1次,连续28天。固本防哮饮预防组给予固本防哮饮13.5 g/(kg·d),于造模第1天开始灌胃,连续84天。取各组小鼠右肺中叶进行HE染色,检测肺组织白细胞介素6(IL-6)、白细胞介素8(IL-8)、肿瘤坏死因子α(TNF-α)mRNA的表达及STAT1蛋白表达。结果 HE染色结果显示,模型组可见肺小叶正常结构破坏,肺泡壁明显增厚、充血、水肿及炎性细胞浸润,气道壁增厚,管腔狭窄;各药物组小鼠肺组织仅有轻度的炎性病变,较模型组明显减轻。与正常组比较,模型组小鼠肺组织STAT1蛋白及IL-6、IL-8、TNF-αmRNA表达水平显著升高(P<0.05);与模型组比较,孟鲁司特钠组和固本防哮饮低、中、高剂量组及预防组小鼠肺组织中STAT1蛋白、IL-6、IL-8 mRNA表达明显降低(P<0.05),孟鲁司特钠组和固本防哮饮中、高剂量组及预防组小鼠肺组织中TNF-αmRNA表达明显降低(P<0.01)。结论固本防哮饮防治支气管哮喘可能与抑制肺组织中STAT1蛋白的活化,降低IL-6、IL-8、TNF-αmRNA的表达有关。
Objective To explore the possible mechanism of Guben anti-asthma drink in prevention and treatment of bronchial asthma. Methods Seventy BALB / c mice were randomly divided into normal group, model group, montelukast sodium group and Guben anti-asthma drink low, medium and high dose group and Guben anti-asthmatic drink prevention group, 10 rats in each group . Except for the normal group, the other mice in each group were sensitized with ovalbumin and challenged with respiratory syncytial virus infection to establish bronchial asthma model. Montelukast sodium group was given montelukast sodium 1.5 mg / (kg · d), Guben anti-asthma drink low, medium and high dose groups were given solid anti-asthma drink 13.5,27.0,54.0 g / (kg · D), the above groups were in the modeling of the first 56 days began to give the corresponding drug gavage once a day for 28 days. Guben anti-asthmatic drink prevention group was given Guben anti-asthmatic drinking 13.5 g / (kg · d), in the first day of modeling gavage for 84 days. The right middle lobe of each group was taken HE staining to detect the expression of IL-6, IL-8, TNF-α mRNA and the expression of STAT1 protein expression. Results The results of HE staining showed that the normal structure of the lung lobes was destroyed, the alveolar walls were obviously thickened, the congestion, edema and infiltration of inflammatory cells, the thickening of the airway wall and the narrowing of the lumen were observed in the model group. Degree of inflammatory lesions, compared with the model group significantly reduced. Compared with the normal group, the expression of STAT1, IL-6, IL-8 and TNF-αmRNA in the model group were significantly increased (P <0.05). Compared with the model group, the montelukast sodium group The expression of STAT1, IL-6 and IL-8 mRNA in the lung tissue of low, middle, high dose and prophylaxis groups of anti-asthmatic diet decreased significantly (P <0.05), while those in montelukast sodium group and Guben anti-asthma drink The expression of TNF-αmRNA in the lung tissue of middle and high dose group and prophylaxis group was significantly decreased (P <0.01). Conclusion Guben anti-asthma drink may be used to prevent and treat bronchial asthma by inhibiting the activation of STAT1 protein and decreasing the expression of IL-6, IL-8 and TNF-αmRNA in lung tissue.